Mumbai: Dr Reddy''''s Laboratories Ltd has received approval from the US Food and Drug Administration to market its anti-infective ciprofloxacin extended-release tablets.

The drug maker also received approval to market rivastigmine tartrate capsules, a generic variant of Novartis'''' Exelon capsules, indicated in the treatment of mild dementia associated with Alzheimer''''s disease and Parkinson''''s disease, USFDA said in statement in its website.